Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

CarrerasPathfinders Enabling the next generation in search of blood cancer cures

Coordinator
Fundacio Institut De Recerca Contra La Leucemia Josep Carreras, Spain
Runs
1 September 2024 to 31 August 2029
Status
Running
EU funding
€1.9m
Total cost
—
Partners
47 organisations in 18 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101126688

What the project is doing

In the project's own words, from its summary on CORDIS.

The CarrerasPathfinder program is new a world-wide unique doctoral program that covers the entire spectrum of research and innovation in blood cancers from understanding disease biology to the implementation of novel processes in the clinical practice. The program will fund 14 excellent Doctoral Candidates (DCs) for a period of 48 months. DCs will perform collaborative PhD projects involving associated partners from different sectors, countries, and disciplines through secondments.

DCs will improve their research capacity and transferable skills through high-quality supervision arrangements and a tailored training program. The program has been designed and will be hosted by the Josep Carreras Leukaemia Research Institute (IJC) which is the first European non-profit institute exclusively devoted to blood cancers. By answering the European needs for human resources, it is fully aligned with the 13 recommendations of the EU Cancer Board’s Draft Mission and the Europe’s Beating Cancer Plan (2021).

The CarrerasPathfinder program has a strong triple-I dimension of internationality, inter-sectorality and interdisciplinarity in training, networking, co-supervision and research. Its specific objectives are:•To develop an excellent doctoral program in blood cancer research conceived as a pilot for a permanent international doctoral program•To equip DCs with a unique skill set boosting effectiveness and innovation capacity. •To promote DCs’ career development and increase their employability in different sectors.•To establish the IJC as a European reference for research and training in blood cancers.•To provide Europe with a new generation of researchers able to address unmet needs and societal challenges of blood cancers.•To contribute to structuring the European research area by collaborating and synergizing with other European key opinion leaders.

Who is involved

OrganisationCityCountryRole
Fundacio Institut De Recerca Contra La Leucemia Josep CarrerasBadalonaSpainCoordinator
University of SharjahSharjahAEAssociatedpartner
Universite Libre De BruxellesBruxellesBelgiumAssociatedpartner
Specialized Hospital for Active Treatment of Hematological DiseasesSofiaBulgariaAssociatedpartner
Ecole Polytechnique Federale De LausanneLausanneSwitzerlandAssociatedpartner
Fondazione per L'istituto Oncologico Di Ricerca (ior)BellinzonaSwitzerlandAssociatedpartner
University of CyprusNicosiaCyprusAssociatedpartner
Ustav Molekularni Genetiky Av Cr V.v.i.Praha 4CzechiaAssociatedpartner
Charite - Universitaetsmedizin BerlinBerlinGermanyAssociatedpartner
Deutsches Krebsforschungszentrum HeidelbergHeidelbergGermanyAssociatedpartner
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften eVMunchenGermanyAssociatedpartner
Mll Munchner Leukamielabor GmbHMunchenGermanyAssociatedpartner
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainAssociatedpartner
Anaxomics Biotech SLBarcelonaSpainAssociatedpartner
Applied Nanoparticles SLBarcelonaSpainAssociatedpartner
Applied Research Using Omic Sciences SLBarcelonaSpainAssociatedpartner
Asociacion Innolife SpainBarcelonaSpainAssociatedpartner
Asociación Española Contra el CáncerMadridSpainAssociatedpartner
Barcelona Supercomputing Center Centro Nacional De SupercomputacionBarcelonaSpainAssociatedpartner
Biocat La Fundacio Bioregio De CatalunyaBarcelonaSpainAssociatedpartner
Consorcio Para La Construccion Equipamiento Y Explotacion Del Laboratorio De Luz SincrotronCerdanyola Del Valles BarcelonaSpainAssociatedpartner
Fundacio Institucio Dels Centres De Recerca De CatalunyaBarcelonaSpainAssociatedpartner
Fundacio Institut De Recerca Biomedica (irb Barcelona)BarcelonaSpainAssociatedpartner
Fundacion Cientifica De La Asociación Espanola Contra El CancerMadridSpainAssociatedpartner
Fundacion Para El Conocimiento MadrimasdMadridSpainAssociatedpartner
Fundació Internacional Josep CarrerasBarcelonaSpainAssociatedpartner
Gavin LucasBarcelonaSpainAssociatedpartner
Mesoestetic Pharma Group S.l.ViladecansSpainAssociatedpartner
Onechain Immunotherapeutics S.l.BarcelonaSpainAssociatedpartner
Quimatryx SLSan SebastianSpainAssociatedpartner
Scienseed SLMadridSpainAssociatedpartner
Universitat Autonoma De BarcelonaCerdanyola Del VallesSpainAssociatedpartner
Universitat De BarcelonaBarcelonaSpainAssociatedpartner
Semmelweis EgyetemBudapestHungaryAssociatedpartner
Humanitas Mirasole SpARozzano (Mi)ItalyAssociatedpartner
Universita Degli Studi Di TorinoTorinoItalyAssociatedpartner
European Hematology AssociationDen HaagNetherlandsAssociatedpartner
Universitetet I OsloOsloNorwayAssociatedpartner
Fundacao Gimm - Gulbenkian Institute for Molecular MedicineLisboaPortugalAssociatedpartner
Institutul National De Cercetare - Dezvoltare in Domeniul Patologiei Si Stiintelor Biomedicale Victor Babes RaBucharestRomaniaAssociatedpartner
Onkoloski Institut LjubljanaLjubljanaSloveniaAssociatedpartner
Biomedicinske Centrum Slovenskej Akademie Vied, Verejna Vyskumna InstituciaBratislavaSlovakiaAssociatedpartner
Novogene UK Company LimitedLondonUnited KingdomAssociatedpartner
University of Newcastle Upon TyneNewcastle Upon TyneUnited KingdomAssociatedpartner
International Society for Experimental HematologyChicagoUnited StatesAssociatedpartner
New York UniversityNew YorkUnited StatesAssociatedpartner
Trustees of Columbia University in the City of New YorkNew YorkUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI